Edition:
United States

Global Markets Headlines

Pfizer-AstraZeneca deal not quite dead yet

Pfizer Inc may have called its $118 billion bid for AstraZeneca Plc a "final" offer, and its British rival sees no prospect of a deal being revived. But Wall Street isn't ready to call in the undertakers.

Politics Video

Politics News